Efinopegdutide: MASH Trials, Liver-Fat Evidence and Safety
Published
Direct answer: Efinopegdutide is an investigational injectable GLP-1/glucagon receptor co-agonist being studied for metabolic dysfunction-associated steatohepatitis (MASH). It has human liver-fat and biopsy evidence, but it is not an approved treatment. The important distinction is between reducing liver fat, improving biopsy findings and demonstrating better long-term health outcomes. Those are different questions. 1–4
Key findings
- Identity matters: MK-6024, JNJ-64565111 and HM12525A are development names for efinopegdutide. They do not identify an approved retail formulation. 5
- The earlier trial measured liver fat: its 24-week imaging result should not be described as a percentage of people cured of MASH. 1,6
- The newer trial measured biopsy outcomes: the November 2026 report concerns adults with MASH and F2–F3 fibrosis. It does not establish prevention of liver transplantation or death. 2,3
- Read percentages with their denominators: the published abstract presents differing analysis denominators. This guide preserves that uncertainty rather than converting reported response percentages into a personal success probability. 2
- Current care has changed since 2023: statements in older papers that no MASH treatment is approved are historical. FDA has since approved resmetirom and a MASH indication for Wegovy injection. 7,8
What efinopegdutide is, and what it is not
The historical study protocol links the names HM12525A, JNJ-64565111 and MK-6024 to efinopegdutide. It describes a subcutaneous study intervention given weekly. A development code helps connect documents across a research program; it is not a brand name, a prescription label or evidence that a seller's vial matches the studied medicine. 5
Efinopegdutide pairs GLP-1 with glucagon receptor activity. That is distinct from the GLP-1/GLP-2 pairing discussed in our dapiglutide guide. A shared “dual agonist” description does not make two drugs interchangeable. Likewise, the GLP-1/glucagon research context overlaps with cotadutide, but results belong to the actual compound, formulation, population and trial tested. 2,3
Study doses below identify trial arms. They are included so readers can distinguish the experiments, not as instructions for treatment, titration or compounding. There is no efinopegdutide prescribing label being supplied by this guide.
Why liver fat and liver scarring need separate answers
MASH involves liver inflammation and injury in the setting of metabolic-associated fatty liver disease. It can progress to serious liver complications. A change in fat content is therefore useful to study, but it does not answer every question about injury or scarring. FDA's current MASH discussion distinguishes biopsy improvement from later outcomes such as liver-related events and survival. 7
An imaging endpoint, a tissue endpoint and a clinical outcome should occupy separate columns in any evidence comparison. Asking which was actually measured prevents a common interpretation error: reading a large percentage reduction in one laboratory or imaging measure as the same percentage reduction in disease risk.
For clinical assessment, noninvasive tests and biopsy also serve different purposes. EASL's practice guideline describes using blood-based scores and liver stiffness measurements to assess fibrosis risk; biopsy is not routinely required for every person with MASLD. A biopsy-defined research population should not be treated as everyone with elevated liver enzymes or an incidental fatty-liver scan. 9
This distinction matters when deciding whether a study applies to a reader. Before considering its result, identify the entry condition, the fibrosis stage, the comparator, the measurement and the follow-up period. A study's eligibility criteria are part of its answer.
Human evidence: the two main liver studies
| Study and design | Population and follow-up | What was assessed | Main interpretation and limit |
|---|---|---|---|
| Romero-Gómez and colleagues, 2023; randomized, open-label phase 2a | 145 participants with NAFLD; 24 weeks | Efinopegdutide 10 mg versus semaglutide 1 mg; MRI-based liver-fat change | Greater relative liver-fat reduction with efinopegdutide; imaging result, not a biopsy cure rate. [1,6] |
| Lawitz and colleagues, November 2026; randomized phase 2b | Adults with biopsy-confirmed MASH and F2–F3 fibrosis; 52 weeks | Three efinopegdutide doses versus placebo; open-label semaglutide reference arm | Reported histologic benefit versus placebo; analysis denominators require care, and long-term clinical benefit is not established. [2,3] |
The 2023 phase 2a result
The earlier publication reports 72 participants assigned to efinopegdutide and 73 to semaglutide. Relative liver-fat reductions were 72.7% versus 42.3%, respectively; body-weight reductions were 8.5% versus 7.1%, with the latter comparison p=0.085. The weight result did not meet the conventional 0.05 threshold. The study was open-label and assessed a 24-week imaging endpoint. 1
The EU results record specifies the calculation: relative reduction equals baseline minus follow-up, divided by baseline. It reports model-based least-squares means and 90% confidence intervals. That is a within-measure relative change, not an absolute percentage-point fall in liver fat and not a count of people whose disease disappeared. 6
For illustration only, a relative reduction of one half would take a hypothetical measured value from 20 to 10, a decrease of 10 percentage points. This arithmetic example is not a participant result. Keeping the denominator visible makes the language easier to check.
The semaglutide comparator was 1 mg in this trial. It should not be silently relabeled as every semaglutide formulation or dose. The study's comparison is useful within its own design; broader treatment rankings need appropriate evidence.
The November 2026 phase 2b report
The original abstract reports 386 randomized participants and 381 treated participants included in the analysis. It reports MASH-resolution counts of 31/55, 31/49 and 35/57 across the efinopegdutide arms, versus 7/53 with placebo. Its methods also say missing end-of-treatment biopsies were considered failures. The abstract's fibrosis endpoint uses different denominators. 2
Evidence limitation: we could not reconcile those analysis sets from the accessible abstract and publisher excerpts. Accordingly, this guide does not supply a reconstructed intention-to-treat resolution rate, a number needed to treat or a universal “chance of success.” The original report is linked so readers can inspect its analysis definitions. A smaller reported denominator must not be assumed to mean every randomized participant was assessed identically.
Merck's November 9 announcement reports primary response percentages of 56%, 63% and 61% across the 4, 7 and 10 mg groups versus 13% with placebo. It reports fibrosis-improvement percentages of 43%, 52% and 34% versus 21%. These are attributed sponsor summaries of the same study, not independent replication. 3
This supports describing a promising phase 2b signal. It does not support calling every dose superior on every endpoint, declaring a cure or selecting a dose for routine practice. The open-label semaglutide arm also does not justify a blanket head-to-head superiority claim.
Safety: efficacy and treatment burden belong together
The newer abstract identifies gastrointestinal events as the most frequent adverse events, with more treatment discontinuation at the highest efinopegdutide dose. 2 Merck reports nausea, vomiting and diarrhea, and more adverse-event-related treatment discontinuation at 10 mg. Its benefit framing should be read alongside this tolerability information. 3
The earlier study's safety findings concern a different population and shorter exposure. A registry's adverse-event tables help check denominators, exposure periods and event categories; those categories should not be collapsed into one undefined “side-effect rate.” The phase 2a record includes both results and a publicly posted protocol/statistical analysis plan. 4,5
A careful safety comparison asks whether an event was any adverse event, serious, judged drug-related or associated with stopping treatment. These are different questions. An absence of a particular event in a modest study also cannot establish that it never occurs.
FDA explains that later, larger clinical studies provide additional information about less common or longer-term adverse effects. A phase 2 result is an evidence step, not a guarantee that the eventual benefit–risk balance is settled. 10 Our broader peptide safety guide explains why human evidence and product quality need separate assessment.
Mechanism and preclinical evidence
The GLP-1/glucagon pairing is a biological rationale for investigating metabolic and liver effects. The protocol discusses GLP-1-associated glucose and weight effects alongside the rationale for adding glucagon activity. Mechanistic reasoning helps explain why a trial was designed; it does not tell us the magnitude of a human clinical benefit. 5
Animal and laboratory findings are not pooled with the human outcomes in this guide. Nor does a liver-fat response by itself isolate how much benefit came from weight change versus direct hepatic effects. A mechanism can be plausible while the clinical questions about durability, safety and meaningful outcomes remain open.
For comparisons across this research area, start with the GLP-1 evidence guide and keep receptor pairing separate from the actual treatment evidence.
Current development, approval and access context
The official NCT05877547 record retrieved November 19, 2026 lists the phase 2b study as completed, with actual completion December 29, 2025 and last update posted January 12, 2026. Its retrieved record does not contain posted results tables. A subsequent journal publication and an older registry update can coexist; each has its own date and purpose. “Completed” describes that trial, not regulatory approval or present recruitment. 11
Efinopegdutide remains described as investigational in the current developer announcement. No approval or public commercial launch should be inferred from a positive study headline. 3
The treatment landscape also prevents an older quotation from becoming current advice. FDA approved Rezdiffra in March 2024 for specified adults with noncirrhotic NASH and moderate-to-advanced scarring, with diet and exercise. FDA's Wegovy MASH announcement describes a later approved indication and continuing work to confirm clinical benefit. These actions concern those specific medicines, not efinopegdutide. 7,8
Online product availability is a separate question from drug development. FDA warns that unapproved GLP-1 products have not undergone its premarket review for safety, effectiveness and quality; products falsely sold for research can have unknown quality. This is general regulatory context, not evidence that FDA tested a particular efinopegdutide seller or vial. 12
A practical checklist for comparing a new headline
| Question to ask | What a useful answer includes | What should remain unknown without it |
|---|---|---|
| What does the percentage describe? | The measured variable, its baseline and the denominator | Whether two headline percentages are comparable |
| Who was included in the analysis? | Randomized, treated and endpoint-analysis populations, with missing-data rules | A reconstructed response rate for everyone enrolled |
| What was the comparison? | Named comparator, dose, duration and masking | Superiority over a different treatment regimen |
| What happened beyond the endpoint? | Discontinuation, adverse events and length of follow-up | Durable benefit or a settled long-term safety profile |
This is an editorial reading aid, not a scoring system validated to predict treatment success. A blank cell should remain a question to resolve rather than an invitation to fill it with a favorable assumption. Readers can apply it to both optimistic headlines and negative summaries: the same source standard should govern each.
Questions worth bringing to the evidence
Is efinopegdutide a weight-loss drug or a liver-disease drug?
The liver studies discussed here address their specified liver populations and endpoints. They should not be turned into a general obesity treatment recommendation. Identify the intended indication before comparing a headline with results from another program.
Does less liver fat mean fibrosis has reversed?
The imaging endpoint and biopsy endpoint answer different questions. Report them separately. A clear evidence summary should also distinguish improvement at a study visit from prevention of future complications.
Can I compare the largest percentage with another peptide's headline?
First check whether both percentages mean the same thing. Relative change, response proportion and percentage-point difference use different denominators. Then compare populations, duration, doses, masking and missing-data handling. A table of large numbers without those features can be misleading.
What would change this assessment?
A clarified analysis-set description would improve interpretation of the newest response figures. Further controlled evidence, longer follow-up, complete safety reporting and any actual regulatory decision would change different parts of the assessment. A new press release alone should not overwrite a study's design limits.
How this guide was prepared
Peptide Dossier's editorial team prepared this selected evidence synthesis with AI assistance under our editorial policy. It is not a systematic review, clinical consultation or claimed clinician review. The 2023 original full report, public protocol and results records, the 2026 original abstract/publisher excerpts, developer announcement and official regulatory context were checked November 18, 2026; the trial records, developer announcement and regulatory context were refreshed November 19, 2026. Full access to the newer publisher report was unavailable; the denominator limitation remains explicit. See about the project and the study explorer for related resources.
References
- Romero-Gómez M et al. Journal of Hepatology, 2023. Phase IIa active-comparator-controlled efinopegdutide study. Original report, institutional PDF. DOI: 10.1016/j.jhep.2023.05.013.
- Lawitz E et al. The Lancet, online November 9, 2026. Phase 2b MASH study. Original abstract. DOI: 10.1016/S0140-6736(26)02043-X.
- Merck. November 9, 2026. Phase 2b results announcement.
- ClinicalTrials.gov. NCT04944992: phase 2a study and posted results. Results first posted November 15, 2023.
- Merck protocol MK-6024-001-02, August 26, 2021. Public protocol and statistical analysis plan.
- EU Clinical Trials Register. 2020-005136-30 results.
- FDA. Wegovy approval for MASH and supporting evidence.
- FDA. March 14, 2024. First treatment approval for NASH with liver scarring.
- EASL–EASD–EASO. 2024. Clinical practice guideline on MASLD.
- FDA. Clinical research in the drug-development process.
- ClinicalTrials.gov. NCT05877547: phase 2b MASH study. Registry update January 12, 2026; retrieved November 19, 2026.
- FDA. Concerns about unapproved GLP-1 drugs.